Cipla (CIPLA) — Financial Results

Cipla reported Q2 FY26 revenue of ₹7,589 crores with 8% YoY growth and 25% EBITDA margin. PAT reached ₹1,351 crores (17.8% margin). The company revised FY26 EBITDA guidance downward to 22.75-24% from 23.5-24.5% due to accelerated R&D investments and Revlimid patent cliff impact (January 2026). Strategic wins include obesity care entry via tirzepatide partnership with Eli Lilly (brand Yurpeak) and first U.S. biosimilar (filgrastim) launch. India business recovered in Q2 after Q1 slowdown; U.S. generics contributed $233M revenue. Net cash position stands at ₹9,901 crores.

📄 View Original Announcement (PDF)

📊 Stock Analysis — CIPLA ✨ Ask AI About This

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

💡 Ask AI about this filing

"How does this financial results affect Cipla Limited's outlook?" "What did Cipla Limited announce on 3 November 2025?" "Is this positive or negative for CIPLA?"

Ask AI Free →

📊 More CIPLA filings

See all CIPLA filings →

🔥 Also filed on 3 November 2025

BEL Bharat Electronics Limited Financial Results ULTRACEMCO UltraTech Cement Limited Corporate Action AMBUJACEM Ambuja Cements Limited Financial Results BAJAJFINSV Bajaj Finserv Limited Financial Results AMBUJACEM Ambuja Cements Limited Financial Results BHARTIARTL Bharti Airtel Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.